REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2022 Conference

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) announced three oral presentations at the Angiogenesis, Exudation, and Degeneration 2022 Conference, occurring from February 11 to 12, 2022. These presentations will include updated interim data from the ongoing Phase II ALTITUDE™ trial of RGX-314, targeting diabetic retinopathy. Notable presentations are scheduled for February 12, covering gene therapy advancements led by experts from renowned institutions. REGENXBIO's NAV® Technology Platform underpins its gene therapy pipeline, reflecting a commitment to innovative treatments.

ROCKVILLE, Md., Feb. 4, 2022 /PRNewswire/ -- 

• Data for Cohort 1 with six months of follow-up from the Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy to be presented

REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral presentations, including updated interim data from the ongoing Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy, will be presented at the Angiogenesis, Exudation, and Degeneration 2022 Conference taking place virtually from February 11 to 12, 2022.

The presentations will be as follows:

Presentation Title: RGX-314 Gene Therapy for Wet AMD
Presenter: Allen C. Ho, M.D., Director of Retina Research, Wills Eye Hospital, Mid Atlantic Retina
Date/Time: Saturday, February 12, 2022, 9:10 a.m. ET

Presentation Title: Update on the AAVIATE Phase 2 Study: Suprachoroidal RGX-314 in Neovascular AMD
Presenter: Rahul N. Khurana, M.D., Northern California Retina Vitreous Associates, Clinical Associate Professor of Ophthalmology, University of California at San Francisco (UCSF)
Date/Time: Saturday, February 12, 2022, 9:30 a.m. ET

Presentation Title: Suprachoroidal RGX-314 Gene Therapy for Diabetic Retinopathy
Presenter: Michael A. Klufas, M.D., Assistant Professor of Ophthalmology, Thomas Jefferson University, Wills Eye Hospital
Date/Time: Saturday, February 12, 2022, 12:20 p.m. ET

About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-angiogenesis-exudation-and-degeneration-2022-conference-301475456.html

SOURCE REGENXBIO Inc.

FAQ

What are the key updates from the RGX-314 Phase II ALTITUDE trial announced by REGENXBIO?

REGENXBIO announced that updated interim data from the Phase II ALTITUDE trial of RGX-314 for diabetic retinopathy will be presented on February 12, 2022.

When and where will the presentations about RGX-314 take place?

The presentations are part of the Angiogenesis, Exudation, and Degeneration 2022 Conference, scheduled for February 11-12, 2022.

Who are the presenters for the RGX-314 updates at the conference?

Presenters include Allen C. Ho, M.D., Rahul N. Khurana, M.D., and Michael A. Klufas, M.D.

What is the significance of the NAV Technology Platform for REGENXBIO?

REGENXBIO's NAV Technology Platform is crucial as it supports the development of their gene therapy candidates across various therapeutic areas.